CTOs on the Move

Xeris Pharmaceuticals

www.xerispharma.com

 
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xerispharma.com
  • 180 North LaSalle Street Suite 1600
    Chicago, IL USA 60601
  • Phone: 844.445.5704

Executives

Name Title Contact Details
Curtis R
Manager of IT Infrastructure and Security Profile

Funding

Xeris Pharmaceuticals raised $41M on 01/07/2016
Xeris Pharmaceuticals raised $10M on 03/08/2018
Xeris Pharmaceuticals raised $45M on 03/08/2018
Xeris Pharmaceuticals raised $27M on 03/11/2021
Xeris Pharmaceuticals raised $30M on 01/03/2022

Similar Companies

TriRx

Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.

Kindeva Drug Delivery

Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

HI-Bio

HI Bio is a clinical stage biotechnology company focused on the development of targeted therapies for patients with immune mediated diseases (IMDs).

Psych Hub

Psych Hub is the worlds largest online platform for mental health education. We train mental health providers, employers, organizations, and individuals on mental health.